$APTO
Aptose Biosciences Inc. Stock $apto

$apto Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000117184320005509 Filed on August 04, 2020

Income Statement

Concept	2020 Q3	2020 Q2	2019 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.740M	$8.980M	$2.810M
YoY Change	155.11%	219.57%	12.4%
% of Gross Profit
Research & Development	$7.519M	$6.866M	$3.491M
YoY Change	58.26%	96.68%	-55.35%
% of Gross Profit
Depreciation & Amortization	$37.00K	$37.00K	$53.00K
YoY Change	12.12%	-30.19%	178.95%
% of Gross Profit
Operating Expenses	$13.29M	$15.88M	$6.346M
YoY Change	89.18%	150.25%	-38.56%
Operating Profit
YoY Change
Interest Expense	$50.00K	$130.0K	$130.0K
YoY Change	-72.22%	0.0%	85.71%
% of Operating Profit
Other Income/Expense, Net	$45.00K	$131.0K	$128.0K
YoY Change	-75.41%	2.34%	91.04%
Pretax Income	-$13.25M	-$15.75M	-$6.220M
YoY Change	93.71%	153.22%	-39.38%
Income Tax
% Of Pretax Income
Net Earnings	-$13.25M	-$15.75M	-$6.218M
YoY Change	93.59%	153.3%	-39.41%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$154.3K	-$206.5K	-$133.8K
COMMON SHARES
Basic Shares Outstanding	87.48M		43.76M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q3	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$132.7M	$82.70M	$35.40M
YoY Change	339.4%	133.62%	91.35%
Cash & Equivalents	$99.73M	$54.11M	$26.90M
Short-Term Investments	$33.00M	$28.60M	$8.500M
Other Short-Term Assets	$115.0K	$117.0K	$168.0K
YoY Change	5.5%	-30.36%	-18.05%
Inventory
Prepaid Expenses	$1.106M	$1.023M	$722.0K
Receivables
Other Receivables
Total Short-Term Assets	$133.9M	$83.86M	$36.27M
YoY Change	337.61%	131.25%	90.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$272.0K	$309.0K	$352.0K
YoY Change	-24.65%	-12.22%	52.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.313M	$1.456M	$1.925M
YoY Change	-29.1%	-24.36%	733.33%
TOTAL ASSETS
Total Short-Term Assets	$133.9M	$83.86M	$36.27M
Total Long-Term Assets	$1.313M	$1.456M	$1.925M
Total Assets	$135.3M	$85.32M	$38.19M
YoY Change	316.69%	123.4%	98.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.529M	$1.903M	$1.240M
YoY Change	30.24%	53.47%	8.2%
Accrued Expenses	$3.378M	$2.892M	$1.486M
YoY Change	52.09%	94.62%	18.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$500.0K
YoY Change
Total Short-Term Liabilities	$5.444M	$5.323M	$3.219M
YoY Change	39.3%	65.36%	34.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.200M
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$700.0K	$800.0K
YoY Change
Total Long-Term Liabilities	$700.0K	$800.0K	$1.200M
YoY Change	-36.36%	-33.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.444M	$5.323M	$3.219M
Total Long-Term Liabilities	$700.0K	$800.0K	$1.200M
Total Liabilities	$6.102M	$6.099M	$4.434M
YoY Change	21.26%	37.55%	84.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$342.4M	-$329.2M	-$287.4M
YoY Change	16.39%	14.56%	8.9%
Common Stock	$429.5M	$366.3M	$291.2M
YoY Change	47.41%	25.79%	15.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$129.2M	$79.22M	$33.76M
YoY Change
Total Liabilities & Shareholders Equity	$135.3M	$85.32M	$38.19M
YoY Change	316.69%	123.4%	98.0%

Cashflow Statement

Concept	2020 Q3	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	-$13.25M	-$15.75M	-$6.218M
YoY Change	93.59%	153.3%	-39.41%
Depreciation, Depletion And Amortization	$37.00K	$37.00K	$53.00K
YoY Change	12.12%	-30.19%	178.95%
Cash From Operating Activities	-$8.270M	-$7.164M	-$5.269M
YoY Change	59.53%	35.97%	-42.62%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$37.00K	$26.00K
YoY Change	-100.0%	42.31%	-74.0%
Acquisitions
YoY Change
Other Investing Activities	-$4.380M	$1.510M	-$8.000M
YoY Change	338.0%	-118.88%	-3300.0%
Cash From Investing Activities	-$4.398M	$1.479M	-$8.026M
YoY Change	322.07%	-118.43%	-5450.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$58.23M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$58.28M	$46.00K	23.61M
YoY Change	342741.18%	-99.81%	104.11%
NET CHANGE
Cash From Operating Activities	-$8.270M	-$7.164M	-5.269M
Cash From Investing Activities	-$4.398M	$1.479M	-8.026M
Cash From Financing Activities	$58.28M	$46.00K	23.61M
Net Change In Cash	$45.62M	-$5.642M	10.32M
YoY Change	-834.3%	-154.69%	306.82%
FREE CASH FLOW
Cash From Operating Activities	-$8.270M	-$7.164M	-$5.269M
Capital Expenditures	$0.00	$37.00K	$26.00K
Free Cash Flow	-$8.270M	-$7.201M	-$5.295M
YoY Change	58.25%	36.0%	-42.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	apto	Amortization Of Rightof Use Assets AmortizationOfRightofUseAssets	690000
CY2019Q4	apto	Amortization Of Rightof Use Assets AmortizationOfRightofUseAssets	461000
CY2020Q2	apto	Interest Accrued On Investments InterestAccruedOnInvestments	-88000
CY2019Q2	apto	Interest Accrued On Investments InterestAccruedOnInvestments	19000
	apto	Interest Accrued On Investments InterestAccruedOnInvestments	-28000
	apto	Interest Accrued On Investments InterestAccruedOnInvestments	19000
CY2020Q2	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities	19000
CY2019Q2	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities	23000
	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities	37000
	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities	47000
CY2020Q2	apto	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
CY2020Q2	apto	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	1837000
CY2019Q4	apto	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	1837000
CY2020Q2	apto	Research And Development Liabilities Current ResearchAndDevelopmentLiabilitiesCurrent	1152000
CY2019Q4	apto	Research And Development Liabilities Current ResearchAndDevelopmentLiabilitiesCurrent	1062000
CY2020Q2	apto	Sharebased Compensation Arrangement By Sharebased Payment Award Maximum Subscription Rate SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumSubscriptionRate	0.175
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000882361
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	87483719
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Registrant Name EntityRegistrantName	Aptose Biosciences Inc.
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Security12b Title Security12bTitle	Common Shares, no par value
	dei	Trading Symbol TradingSymbol	apto
CY2020Q2	apto	Sharebased Compensation Arrangement By Sharebased Payment Award Maximum Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares	13400000
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	28610000
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1903000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1960000
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2892000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3058000
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4313000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4298000
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	46386000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	34649000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12102000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1230000
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7701000
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	568000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12102000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1230000
CY2020Q2	us-gaap	Assets Assets	85318000
CY2019Q4	us-gaap	Assets Assets	100476000
CY2020Q2	us-gaap	Assets Current AssetsCurrent	83862000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	98766000
CY2020Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	1456000
CY2019Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1710000
CY2020Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	28607000
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	17740000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	17758000
CY2020Q2	us-gaap	Cash Cash	2942000
CY2019Q4	us-gaap	Cash Cash	1640000
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54112000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79842000
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	59754000
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16581000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	79842000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15299000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	54112000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26898000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5642000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10317000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-25730000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11599000
CY2020Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	51170000
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	78202000
CY2020Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2019Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	76298719
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	76108031
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	76298719
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	76108031
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	366337000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	365490000
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15765000
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6209000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27291000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11706000
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top"><td style="width: 0.5in"></td> <td style="width: 0.25in"><div style="display: inline; color: #010000">(e)</div></td> <td style="text-align: justify">Concentration of risk:</td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company is subject to credit risk from the Company's cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of <div style="display: inline; font-style: italic; font: inherit;">R1</div>-low or A-low investments and the Company invests only in instruments that are issued by highly rated Canadian corporations which are capable of prompt liquidation.</div></div></div></div></div>
CY2020Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	18400000
CY2020Q2	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	3000
CY2019Q4	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	18000
CY2020Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	37000
CY2019Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	53000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	78000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	82000
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2020Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-3000
CY2019Q2	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-10000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	1000
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1488000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1739000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y255D
CY2020Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3000
CY2019Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-10000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	3000
CY2020Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	15000
CY2019Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	2000
CY2019Q2	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	183000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	76000
CY2020Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	116000
CY2019Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	128000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	439000
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9015000
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2855000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14915000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5115000
CY2020Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-114000
CY2019Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	70000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-57000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-75000
CY2020Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1008000
CY2019Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	164000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-166000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	90000
CY2020Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets
CY2019Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	73000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-24000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	67000
CY2020Q2	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	137000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	220000
CY2020Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims
CY2019Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	360000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	360000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1395000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	545000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	119000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	463000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	268000
CY2020Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	100476000
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5323000
CY2020Q2	us-gaap	Liabilities Liabilities	6099000
CY2019Q4	us-gaap	Liabilities Liabilities	6550000
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	85318000
	us-gaap	Operating Lease Cost OperatingLeaseCost	289000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	521000
CY2020Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	115000
CY2019Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	107000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	229000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	231000
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1304000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1532000
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	528000
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	6346000
	us-gaap	Operating Expenses OperatingExpenses	27715000
	us-gaap	Operating Expenses OperatingExpenses	11946000
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	134000
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	141000
	us-gaap	Operating Lease Cost OperatingLeaseCost	267000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5539000
CY2020Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46000
CY2019Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23613000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	482000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29791000
CY2020Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1479000
CY2019Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8026000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10948000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8050000
CY2020Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7164000
CY2019Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5269000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15254000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10143000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-15750000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-6218000
	us-gaap	Net Income Loss NetIncomeLoss	-27276000
	us-gaap	Net Income Loss NetIncomeLoss	-11724000
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	131000
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	128000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	439000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	222000
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	15881000
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	776000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1011000
CY2020Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	134000
CY2019Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	120000
	us-gaap	Operating Lease Payments OperatingLeasePayments	265000
	us-gaap	Operating Lease Payments OperatingLeasePayments	219000
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1837000
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1570000
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1147000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1376000
CY2020Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0543
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0543
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y219D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y109D
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	252000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	257000
CY2020Q2	us-gaap	Other Assets Current OtherAssetsCurrent	117000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	19000
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	309000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	334000
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	141000
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-15000
CY2019Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	9000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-15000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	18000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-15000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	18000
CY2020Q2	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-1516000
CY2019Q2	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	8000000
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	10895000
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	8000000
CY2020Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts
CY2019Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	142000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	142000
CY2020Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37000
CY2019Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	53000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	50000
CY2020Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1023000
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1025000
CY2020Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	46000
CY2019Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	19000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	482000
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6866000
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3491000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12800000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6831000
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-329191000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-301915000
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax
CY2019Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	267000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.84
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.93
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	47000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	71000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	130000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6272000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1789000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.61
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.97
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.36
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.30
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5941000
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11951000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4489000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6078000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.84
CY2020Q2	us-gaap	Share Based Compensation ShareBasedCompensation	7701000
CY2019Q2	us-gaap	Share Based Compensation ShareBasedCompensation	568000
	us-gaap	Share Based Compensation ShareBasedCompensation	12102000
	us-gaap	Share Based Compensation ShareBasedCompensation	1230000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	645000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	80000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.32
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	40000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	685000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	80000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	7.01
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.859
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.839
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0128
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.023
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4190000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3257000
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.91
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.11
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.83
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10786000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5654000
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.79
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.87
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.55
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.11
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	4.23
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.87
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.59
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	76251000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y219D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y146D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y109D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y328D
CY2020Q2	us-gaap	Short Term Investments ShortTermInvestments	28610000
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	17758000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	191000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	23000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	482000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	19000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	93926000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	79219000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	14081000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	33756000
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top"><td style="width: 0.5in"></td> <td style="width: 0.25in"><div style="display: inline; color: #010000">(c)</div></td> <td style="text-align: justify">Significant accounting policies, estimates and judgments:</td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">six</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020, </div>there have been <div style="display: inline; font-style: italic; font: inherit;">no</div> changes to our significant accounting policies as described in our Annual Report on Form <div style="display: inline; font-style: italic; font: inherit;">10</div>-K for the fiscal year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The condensed consolidated interim financial statements include estimates, which, by their nature, are uncertain. Significant accounting policies and estimates made by management are the assumptions used in determining the valuation of share-based compensation and the estimates related to prepaid and accrued research and development costs.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The impacts of such estimates are pervasive throughout the condensed consolidated interim financial statements and <div style="display: inline; font-style: italic; font: inherit;"> may </div>require accounting adjustments based on future occurrences.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.</div></div></div></div></div>
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	76275000
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46474000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43178000

Files In Submission

Name	View Source	Status
0001171843-20-005509-index-headers.html	Edgar Link	pending
0001171843-20-005509-index.html	Edgar Link	pending
0001171843-20-005509.txt	Edgar Link	pending
0001171843-20-005509-xbrl.zip	Edgar Link	pending
apto-20200630.xml	Edgar Link	completed
apto-20200630.xsd	Edgar Link	pending
apto-20200630_cal.xml	Edgar Link	unprocessable
apto-20200630_def.xml	Edgar Link	unprocessable
apto-20200630_lab.xml	Edgar Link	unprocessable
apto-20200630_pre.xml	Edgar Link	unprocessable
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
f10q_080420p.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
logo.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APTO
Aptose Biosciences Inc. Stock $apto

2020 Q3 Form 10-Q Financial Statement

#000117184320005509 Filed on August 04, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APTO Aptose Biosciences Inc. Stock $apto

2020 Q3 Form 10-Q Financial Statement

#000117184320005509 Filed on August 04, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APTO
Aptose Biosciences Inc. Stock $apto